<DOC>
	<DOCNO>NCT02674880</DOCNO>
	<brief_summary>The objective study test effect HMW-HA NIV effectiveness patient admit sub-intensive care unit respiratory failure due acute exacerbation COPD .</brief_summary>
	<brief_title>Hyaluronic Acid Acute Exacerbation COPD - Duration Of Noninvasive Assistance</brief_title>
	<detailed_description>The objective study test effect HMW-HA NIV effectiveness patient admit sub-intensive care unit respiratory failure due acute exacerbation COPD . The design parallel-arm , single-blind , placebo-controlled randomized clinical trial . Eighty patient , age eighteen year old , admit respiratory failure primarily due COPD exacerbation require non-invasive ventilation enrol randomized study treatment ( active placebo ) . All patient treat NIV deliver use Hamilton C1 ventilator medical therapy accord current guideline ( inhaled long-acting b2 agonist , inhale long-acting anticholinergic , inhaled systemic corticosteroid , antibiotic ) . Patients randomize active intervention group also receive HMW-HA ( YabroÂ® - 5 ml saline contain 0.3 % hyaluronic acid sodium salt ) via nebulizer b.i.d. , patient randomize control group receive match placebo . Patients treat wean NIV failure , define oro-tracheal intubation death .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Aged 18 year age older Admitted respiratory failure primarily due COPD exacerbation Requiring noninvasive ventilation Respiratory distress , evidence moderatetosevere dyspnea use accessory muscle respiration Hypercapnic respiratory failure High respiratory rate Respiratory arrest need immediate intubation Upper airways obstruction Facial trauma Inability cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>